Pauliina Tuomikoski1, Pia Ebert, Per-Henrik Groop, Petri Haapalahti, Hanna Hautamäki, Mats Rönnback, Olavi Ylikorkala, Tomi S Mikkola. 1. From the Department of Obstetrics and Gynecology, Helsinki University Central Hospital; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki; Division of Nephrology, Department of Medicine, Helsinki University Central Hospital; and Division of Clinical Physiology and Nuclear Medicine, Helsinki University Central Hospital, Helsinki, Finland.
Abstract
OBJECTIVE: Observational studies indicate that postmenopausal hormone therapy (HT) prevents cardiovascular disease, but randomized clinical trials have not confirmed this effect. Hot flushes were more likely to be present in women starting HT in observational studies, whereas these symptoms were mild or absent among women attending randomized clinical trials. We hypothesized that vascular function may differ in women with and without vasomotor hot flushes. METHODS: One hundred forty-three recently postmenopausal women showing a broad range of variation in hot flushes were studied with radial artery tonometry. Pulse wave analyses were assessed at baseline and after nitroglycerin and salbutamol challenges. Wilcoxon signed rank test was used for paired comparisons after challenges with nitroglycerin and salbutamol. RESULTS: Neither baseline arterial stiffness nor endothelial function differed between women without or with mild, moderate, or severe hot flushes. However, after nitroglycerin challenge, the time to the onset of the reflected wave (dependent on pulse wave velocity) was 9.5% longer (P=.014), and the time to the first systolic peak (dependent on the rapid phase of ventricular ejection) was 13.9% longer (P=.025) in women with severe hot flushes as compared with asymptomatic women. CONCLUSION: Women with severe vasomotor hot flushes show greater vascular responsiveness to nitroglycerin than women without hot flushes. This may partially explain the conflicting data between observational and randomized HT studies. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00668603 LEVEL OF EVIDENCE: II.
OBJECTIVE: Observational studies indicate that postmenopausal hormone therapy (HT) prevents cardiovascular disease, but randomized clinical trials have not confirmed this effect. Hot flushes were more likely to be present in women starting HT in observational studies, whereas these symptoms were mild or absent among women attending randomized clinical trials. We hypothesized that vascular function may differ in women with and without vasomotor hot flushes. METHODS: One hundred forty-three recently postmenopausal women showing a broad range of variation in hot flushes were studied with radial artery tonometry. Pulse wave analyses were assessed at baseline and after nitroglycerin and salbutamol challenges. Wilcoxon signed rank test was used for paired comparisons after challenges with nitroglycerin and salbutamol. RESULTS: Neither baseline arterial stiffness nor endothelial function differed between women without or with mild, moderate, or severe hot flushes. However, after nitroglycerin challenge, the time to the onset of the reflected wave (dependent on pulse wave velocity) was 9.5% longer (P=.014), and the time to the first systolic peak (dependent on the rapid phase of ventricular ejection) was 13.9% longer (P=.025) in women with severe hot flushes as compared with asymptomatic women. CONCLUSION:Women with severe vasomotor hot flushes show greater vascular responsiveness to nitroglycerin than women without hot flushes. This may partially explain the conflicting data between observational and randomized HT studies. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00668603 LEVEL OF EVIDENCE: II.
Authors: Rebecca C Thurston; Samar R El Khoudary; Kim Sutton-Tyrrell; Carolyn J Crandall; Ellen Gold; Barbara Sternfeld; Faith Selzer; Karen A Matthews Journal: Menopause Date: 2011-10 Impact factor: 2.953
Authors: Emily D Szmuilowicz; JoAnn E Manson; Jacques E Rossouw; Barbara V Howard; Karen L Margolis; Nancy C Greep; Robert G Brzyski; Marcia L Stefanick; Mary Jo O'Sullivan; Chunyuan Wu; Matthew Allison; Diederick E Grobbee; Karen C Johnson; Judith K Ockene; Beatriz L Rodriguez; Gloria E Sarto; Mara Z Vitolins; Ellen W Seely Journal: Menopause Date: 2011-06 Impact factor: 2.953
Authors: Rebecca C Thurston; Kim Sutton-Tyrrell; Susan A Everson-Rose; Rachel Hess; Lynda H Powell; Karen A Matthews Journal: Menopause Date: 2011-04 Impact factor: 2.953
Authors: Rebecca C Thurston; Samar R El Khoudary; Ping Guo Tepper; Elizabeth A Jackson; Hadine Joffe; Hsiang-Yu Chen; Karen A Matthews Journal: Stroke Date: 2015-11-17 Impact factor: 7.914
Authors: Virginia M Miller; Juliana M Kling; Julia A Files; Michael J Joyner; Ekta Kapoor; Ann M Moyer; Walter A Rocca; Stephanie S Faubion Journal: Menopause Date: 2018-06 Impact factor: 2.953
Authors: Rebecca C Thurston; Samar R El Khoudary; Kim Sutton-Tyrrell; Carolyn J Crandall; Barbara Sternfeld; Hadine Joffe; Ellen B Gold; Faith Selzer; Karen A Matthews Journal: J Clin Endocrinol Metab Date: 2012-07-31 Impact factor: 5.958